Display options
Cite
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012;3(4):157-64doi: 10.1177/2042098612446473.
Dore, D. D., Seeger, J. D., & Chan, K. A. (2012). Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Therapeutic advances in drug safety, 3(4), 157-64. https://doi.org/10.1177/2042098612446473
Dore, David D, et al. "Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance." Therapeutic advances in drug safety vol. 3,4 (2012): 157-64. doi: https://doi.org/10.1177/2042098612446473
Dore DD, Seeger JD, Chan KA. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473. PMID: 25083233; PMCID: PMC4110848.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Drug Saf. 2012 Aug;3(4):157-64. doi: 10.1177/2042098612446473.

Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.

Therapeutic advances in drug safety

David D Dore, John D Seeger, K Arnold Chan

Affiliations

  1. Brown University, Box G-121-7, 121 South Main Street, Providence, RI 02912, USA.
  2. OptumInsight Epidemiology, Waltham, MA; Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School/Brigham and Women's Hospital, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
  3. OptumInsight Epidemiology, Waltham, MA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.

PMID: 25083233 PMCID: PMC4110848 DOI: 10.1177/2042098612446473

Abstract

OBJECTIVES: As part of a regulatory postmarketing commitment, we assessed the risk of claims for thyroid and pancreatic cancer among users of exenatide using an active drug safety surveillance system.

METHODS: This active surveillance assessment used cohort methodology and commercial health insurance claims data to identify initiators of exenatide and propensity score-matched initiators of metformin or glyburide between June 2005 and September 2009, with up to 1 year of follow up through December 2009. The primary analysis estimated absolute and relative risk (RR) of inpatient or outpatient claims with diagnosis codes for thyroid neoplasm (benign or malignant) or pancreatic malignancies after exclusion of patients with a history of the same diagnosis at baseline.

RESULTS: Among the matched comparison cohorts (N ≈ 32,800 each), there were 37 claims-suggested thyroid malignancies among exenatide initiators and 26 among metformin or glyburide initiators [RR 1.4; 95% confidence interval (CI) 0.8-2.4]. This association was attenuated when limited to inpatient thyroid cancer claims (RR 0.9; CI 0.3-2.6). Exenatide use was not associated with an increased risk of benign thyroid neoplasm (RR 0.7; CI 0.3-1.7), or pancreatic cancer (RR 0.8; CI 0.5-1.6).

CONCLUSIONS: Use of exenatide was associated with a modestly higher incidence of inpatient and outpatient claims, but not inpatient claims for thyroid malignancies. Exenatide was not associated with higher risk of benign thyroid neoplasm or pancreatic cancer. Misclassification of outcomes and exposure, and residual confounding remain limitations of this analysis to be considered when interpreting the results. We have initiated a formal epidemiologic investigation to explore these relationships.

Keywords: active safety surveillance; exenatide; pancreatic cancer; safety signal; thyroid cancer

References

  1. Diabetes Obes Metab. 2011 Jun;13(6):559-66 - PubMed
  2. Cancer Causes Control. 2007 Jun;18(5):561-9 - PubMed
  3. Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):393-7 - PubMed
  4. Int J Epidemiol. 2008 Apr;37(2):382-5 - PubMed
  5. Med Care. 2007 Oct;45(10 Supl 2):S58-65 - PubMed
  6. J Clin Epidemiol. 2000 Dec;53(12):1248-57 - PubMed
  7. Diabetologia. 2009 Sep;52(9):1766-77 - PubMed
  8. Curr Med Res Opin. 2009 Apr;25(4):1019-27 - PubMed
  9. Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 - PubMed
  10. Am J Epidemiol. 1995 Nov 15;142(10):1103-12 - PubMed
  11. N Engl J Med. 2010 Mar 4;362(9):774-7 - PubMed
  12. Gastroenterology. 2011 Jul;141(1):150-6 - PubMed
  13. Med Care. 1981 Jun;19(6):658-64 - PubMed
  14. Drug Saf. 2006;29(11):1069-75 - PubMed

Publication Types